Let's assume that we all recognize this, and let's assume, furthermore, that the Department of National Defence recognizes this. Let's suppose further that the Department of National Defence recognizes and acknowledges that symptoms such as insomnia, anxiety and depression will be not uncommon in operational environments.
Then the question that needs to be asked is: by what logic and reason can they justify the use of a drug whose safe use—or more accurately, whose safer use—requires that the drug be immediately discontinued at the onset of those symptoms?
I would propose that if we are arguing that those conditions exist in theatre—and they certainly do—then we really shouldn't be using mefloquine in that environment.